EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim By Ogkologos - September 18, 2025 64 0 Facebook Twitter Google+ Pinterest WhatsApp Vivlipeg is highly similar to the reference product Neulasta, which was authorised in the EU in 2002 Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR FDA Approves Trifluridine and Tipiracil with Bevacizumab for Previously Treated Metastatic... August 18, 2023 Using Artificial Intelligence to Classify Lung Cancer Types, Predict Mutations October 10, 2018 Longer Duration of Treatment with ICIs Associated with a Higher Rate... March 5, 2025 Approval Expanded for Venetoclax in Chronic Lymphocytic Leukemia June 22, 2018 Load more HOT NEWS Study Finds Most Women Who ‘Go Flat’ After Mastectomy Are Happy... Cancer in My Community: Developing Pediatric Palliative and Supportive Care in... Zenocutuzumab Approved to Treat Lung and Pancreatic Cancers with Rare Genetic... Makeup Artist Gives Breast Cancer Survivors Free Makeovers
